Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Despite FDA Black Box Warning and Restriction to Second-Line Use, Clinicians Widely Use Long-Acting Beta2 Agonists as First-Line Treatment for Mild Asthma
April 11th, 2007
Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that even despite the FDA's black box warning and restriction to second-line use, clinicians widely use long-acting beta2 agonists (LABAs) as first-line treatment for mild asthma. According to the new Physician & Payer Forum report Asthma: The Impact of Reimbursement and Disease Management Programs on Asthma Treatment, 39% of primary care physicians say they most frequently use a single-inhaler LABA as first-line treatment for mild asthma, and a further 33% use GlaxoSmithKline's Advair - a LABA- containing combination - most frequently. As many as 41% of...
Source: Immunotherapy Weekly (2007-04-11)
|
